Recombinant il-9 antibodies and uses thereof
CA 2521826 C · Owner: Medimmune, Inc. · Inventors: Wu, Herren; Tang, Ying; Watkins, Jeffry D.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and compositions preventing treating, managing, and/or ameliorating diseases and disorders associated with aberrant expression and/or activity of IL 9 or IL-9 receptor or subunits thereof autoimmune diseases, inflammatory diseases proliferative diseases, and , infections comprising administration of one or more antibodies thereof that immunospecifically bind to an IL-9 polypeptide. The invention also encompasses methods and compositions for diagnosing monitoring, and prognosing these , disorders. The …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 12, 2004 and granted August 6, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 12, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 12, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.